Drug Interactions With Risk of QT-prolongation in a General Hospital
Information source: Katholieke Universiteit Leuven
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: QT-prolongation
Intervention: Haloperidol (Drug)
Phase: N/A
Status: Completed
Sponsored by: Katholieke Universiteit Leuven Official(s) and/or principal investigator(s):
Eline Vandael, PhD-student, Principal Investigator, Affiliation: Katholieke Universiteit Leuven
Summary
In this epidemiological point prevalence study, medication profiles of patients with
haloperidol treatment will be checked for drug interactions with risk of QT-prolongation.
Additional clinical risk factors for developing QT-prolongation and safety measurements will
be documented.
Clinical Details
Official title: Drug Interactions With Risk of QT-prolongation in a General Hospital: an Epidemiological Point Prevalence Study
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: QTc-interval (corrected for heart rate)
Secondary outcome: number of drug interactions (with risk of QT-prolongation)
Detailed description:
Study design: epidemiological point prevalence study
Target population: Patients with haloperidol treatment
The following aspects will be investigated:
- The medication profiles will be checked for drug interactions with risk of
QT-prolongation.
- Clinical risk factors for developing QT-prolongation (gender, age, (history of)
cardiovascular disease, comorbidity,...) and lab results will be collected.
- Safety measurements (e. g. ECG) will be documented.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- treatment with haloperidol (started in the hospital)
Exclusion Criteria:
- age < 18 years
Locations and Contacts
Universitair Ziekenhuis Leuven, Leuven 3000, Belgium
Additional Information
Starting date: July 2013
Last updated: June 10, 2014
|
